43results about How to "Small residual" patented technology

The invention relates to a salbutamol sulfate film-controlled sustained-release pellet capsule. The sustained-release film of the pellet adopts Kollicoat SR30D as a film-forming material, and the pellet core contains high-expandability sodium carboxymethyl starch, and pharmaceutically acceptable The commonly used excipients of the sustained-release pellets, the excipient is preferably microcrystalline cellulose, wherein, the sodium carboxymethyl starch in the pellet core accounts for 5-20% of the weight of the pellet core. The sustained-release coating film comprises Kollicoat SR30D, plasticizer triethyl citrate and anti-sticking agent talcum powder, and its ratio is preferably Kollicoat SR 30D: triethyl citrate: talcum powder=30:1:4, coating weight gain Preferably it is 19 to 38%. Because the ball core contains sodium carboxymethyl starch, which has high water swelling property, it will swell obviously after absorbing water, resulting in the expansion of the slow-release coating film, the thickness becomes thinner, the pore size of the water-permeable micropores becomes larger, and the permeability becomes better. , which compensates for the decrease in permeability caused by membrane aging, so that the release rate in the middle and late stages is basically constant, and the residue in the end stage is small, which can always maintain a stable release performance within the validity period.

The invention relates to a venlafaxine hydrochloride film-controlled slow-release pellet capsule. A slow-release film of the venlafaxine hydrochloride film-controlled slow-release pellet utilizes Kollicoat SR30D as a film-formation material. A pellet core of the venlafaxine hydrochloride film-controlled slow-release pellet contains low-substituted hydroxyprepyl cellulose having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 10 to 40wt% of low-substituted hydroxyprepyl cellulose. The slow-release film comprises Kollicoat SR30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Kollicoat SR30D to triethyl citrate to talcum powder is 30: 1: 4 and a film weight increasing ratio is in a range of 21 to 39%. The venlafaxine hydrochloride film-controlled slow-release pellet comprises the pellet core containing low-substituted hydroxyprepyl cellulose having high water expansibility and thus after absorbing water, the venlafaxine hydrochloride film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the venlafaxine hydrochloride film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.